Two chr15q25.1 SNPs (rs588765 and rs1051730) exhibit statistically significant associations with quitting success in individuals randomized to placebo and to NRT, but not in individuals randomized to other pharmacotherapies. These results were obtained by analysis of a total of 2,633 self-identified White participants from eight RCTs containing 26 therapy randomization arms, adjusted for PG, RCT arm, demographics, dependence measures, and population genetic variation (and chr15q25.1 SNPs, where appropriate). rs578776, another chr15q25.1 SNP, is not statistically significantly associated with abstinence at either timepoint or in any PG. This may be due to its more modest effect size or its inverse association with smoking heaviness [30]. rs588765 associations with abstinence appear to be somewhat smaller in magnitude than those observed with rs1051730, concordant with previously observed effects on smoking heaviness [30]. Focusing on the results of analysis of rs1051730, we observed that the minor allele is associated with reduced abstinence in the PLA PG at EOT and at 6MO, and with increased abstinence in the NRT PG at 6MO. The directionality of the effect on abstinence in individuals prescribed PLA is expected,
